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Abstract: Staphylococcus aureus, one of the major pathogenic bacteria, is associated with 
substantial morbidity and mortality. The disease burden of staphylococcal infections is 
significant, which is primarily attributed to its adaptability and resistance to environmental 
stresses.  S. aureus has the ability to develop multiple resistances to antimicrobial agents. 
These high resistances make pathogenicity of S. aureus one of the most complex mechanisms 
to understand and manage. Proteomic approaches show great potential in exploring microbial 
adaptation strategies, ability to cause disease by pathogenic bacteria and the development of 
diagnostic tools. A summary of the latest developments in the application of proteomic 
technologies to understand resistance mechanisms in S. aureus and their future role in anti-
staphylococcal vaccine and/or drug discovery is given here. 
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1. INTRODUCTION 
Research in microbiological sciences has entered the post-genomic era more than a 
decade ago now. Proteomic and bioinformatics methods have emerged as powerful tools to 
investigate physiological conditions, mutations, changes in response to external factors and 
adaptation [1, 2]. Rapid developments in research tools used in proteome analysis i.e. one-
dimensional polyacrylamide gel electrophoresis (ID-PAGE), two-dimensional electrophoresis 
(2DE), Matrix Assisted Laser Desorption/Ionization-Time of Flight-Mass Spectrometry 
(MALDI-TOF-MS) and Liquid Chromatography-Mass Spectrometry/Mass Spectrometry 
(LC-MS/MS) has allowed the identification and quantification of global protein-protein and 
protein-ligand interactions named as the ‘interactome’. The genome sequence only provides 
the blueprint of life whereas the proteome brings this genome sequence to real life [2]. 
Identification of proteins has substantial research applications in life and health sciences 
including bio-prospecting, detection and cause of diseases and drug discovery. Protein 
expression profiling is an excellent approach not only to expressed protein pattens,depending 
on environmental conditions, but also to show to what extent each single protein is expressed. 
This proteomic view of the cell’s physiology provides global information on basic cell 
functionalities, on metabolism and/or on stress/starvation responses [3]. 
The pathogenesis of S. aureus is a complex process that involves the strongly coordinated 
synthesis of cell wall-associated proteins and extracellular toxins. Methicillin-resistant 
Staphylococcus aureus (MRSA) is at present the most commonly identified antibiotic-
resistant pathogen in many parts of the world [4, 5]. Hospital-acquired MRSA infection 
increases morbidity, the risk of mortality and costs [6]. The societal costs accrue either 
directly or indirectly and financial repercussions include the costs for containment of 
outbreaks and changes to empiric antibiotic prescribing habits.  Plowman et al. [7] estimated 
the costs of all hospital-acquired MRSA to the National Health Service in England to be ca. 
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£1 billion, including community costs of over £50 million.  In Australia, as in most of the 
world, antimicrobial resistance in S. aureus is a major impediment to effective treatment. An 
Australian survey of S. aureus bacteraemia from 1999 to 2002 documented 3,129 episodes 
[8]. 
Pathogenicity of S. aureus is determined by the ability of the organism to express 
multiple virulence factors [9].  The existence of a great variety of virulence factors enables S. 
aureus to cause a broad spectrum of infections ranging from superficial abscesses, 
osteomyelitis, endocarditis, and toxic shock syndrome [10]. These illnesses cannot always be 
successfully treated with commonly used antibiotics and because MRSA isolates are 
becoming increasingly prevalent in the community, additional control strategies are urgently 
needed.  A vaccine for S. aureus can offer such a mechanism which would boost the immune 
system to eradicate the infecting microbe. Whole genome analysis of S. aureus isolates have 
changed the way investigators approach the classical questions asked about the bacterial-host 
interaction.  Proteomic studies have provided new insights into bacterial pathogenesis and 
vaccine discovery concepts. New opportunities are arising to use proteomic approaches to 
understand the regulatory and adaptation mechanisms of S. aureus. This review will discuss 
recent advances in S. aureus proteomics. 
 
2. PROTEOMIC METHODS USED TO INVESTIGATE S. AUREUS 
PATHOGENESIS 
New approaches to study pathogenic bacteria using combined technologies of genomics, 
proteomics and bioinformatics is rapidly increasing globally. The use of proteomic tools can 
lead to the identification of immunogenic proteins that may be potential vaccine targets as 
well as improving the understanding of antibiotic action. Proteomics has generated innovative 
and valuable information on bacterial pathogens and will continue to be an important source 
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of information in the coming years [11]. Proteomic investigations were initially developed 
based on ID-PAGE and 2DE. Recently, the 2DE gel approach combined with mass 
spectrometry for protein identification was used to create master gels of extracellular proteins 
of S. aureus in order to study the regulatory network involved in the pathogenicity of this 
organism [12]. Furthermore, cytoplasmic and membrane proteins of S. aureus were analyzed 
by gel-free proteomic approaches [13]. Graham et al. [14] reviewed a basic overview of the 
applications of mass spectrometry in protein identification and ways to reduce the protein 
complexity of microbial samples in gel-based and gel-free methodologies.  
Protein sample preparation is a vital part of proteomic analysis. Considering the 
importance of MRSA, proteomic methods particularly focusing on the preparation, 
identification and analysis of different protein fractions have been developed [15]. 
Nandakumar et al. [16] described a method to lyse cells with lysostaphin, which lyses 
staphylococcal peptidoglycan, followed by solubilization with urea, thiourea, 
amidosulfobetaine 14 (ASB 14) and dithiothreitol (DTT) in order to generate membrane/cell 
wall proteome map of S. aureus. This method minimizes the contamination from cytosolic 
proteins. Globally research efforts have been made to correlate transcriptomic and proteomic 
data [13] to streamline the process of peptide identification [17]. A variety of proteomics 
techniques to study S. aureus infections are available now (see a review by Francois et al. 
[18]). 
 
3. CURRENT STATUS OF PROTEOMIC AND BIOINFORMATIC TOOLS IN S. 
AUREUS VIRULENCE AND ANTIBIOTIC RESISTANCE MECHANISM 
INVESTIGATIONS 
The numbers of different proteins produced by S. aureus are more than genes [19].  
Though a great wealth of S. aureus genomic information is available now, yet information on 
 6 
functional proteomics is limited.  Therefore, for a better understanding of virulence factors 
and resistance mechanisms to antibiotics, it is important to know the functionalities of the 
proteins involved. An example of how important it is to find out the functional elements of an 
operative protein can be seen in Boisset et al. [20] study. It was suggested that Rot, a 
transcriptional regulatory protein, activated the synthesis of several exoproteins through the 
indirect action of RNAIII on many downstream genes. Thus emphasizing the regulatory role 
played by RNAIII and its 3′ domain in establishing a network of S. aureus virulence factors. 
A recent report based on transcriptomic and proteomic analysis of S. aureus showed that 
RsaE regulates the synthesis of proteins involved in various metabolic pathways of S. aureus 
[21]. A coordinated action of multiple regulators, transcriptional regulatory proteins, the 
alternative sigma B factor and the regulatory RNAIII are the major tools used by S. aureus for 
the expression of numerous virulence factors and causing a diverse range of infections [22, 
23]. This complexity of regulatory networks is a vital weapon of this pathogen to integrate 
multiple external signals.  
Many researchers are currently using tools to look for signal peptide sequences and 
structural motifs located within genomic sequences in order to develop vaccines.  Genome 
sequences of ten S. aureus strains have been published to date (www.tigr.org; 
www.ncbi.nlm.nih.gov). There are 2600-2700 open reading frames for these strains. Despite 
the detailed availability of genome information, the function of at least one thousand proteins 
encoded by these genes is still unknown [19]. The availability of genomic information has 
enabled the parallel use of microarrays and proteomics in S. aureus resistance and 
pathogenicity studies. Mapping of membrane-associated proteins provides a benchmark for 
biological experimentation such as strain comparisons of pathogens with differing modes of 
pathogenicity and antibiotic resistance mechanisms, and can aid in the definition of vaccine 
and therapeutic targets [24]. Brötz-Oesterhelt et al. [25] reviewed the major achievements of 
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proteomic approaches to investigate bacterial survival and adaptation networks with a special 
emphasis on the stress induced by antibiotic treatment. They also explored the possibilities of 
applying bacterial proteomic studies directly for the antibacterial drug-discovery process. 
Proteome analyses of S. aureus to investigate cell physiology and regulatory networks 
have revealed valuable information. Gel-based proteomics was considered as an extremely 
valuable tool in microbial physiology that had the flexibility to be used with various 
visualization and quantitation software programs for rapid and high-output of data from 
multiple samples [19]. A proteomic comparison made on growing and non-growing S. aureus 
cells showed higher production of enzymes involved in protein synthesis, transcription, and 
glycolysis in exponentially growing cells than stationary-phase cells [2]. Pieper et al. [26] 
compared the proteome maps of three isogenic strains of S. aureus to determine differences 
in their resistance to vancomycin. Comparative protein abundance analysis showed high 
expression of enzymes involved in the purine biosynthesis pathway in a vancomycin-resistant 
strain. A more recent report verified the expression of proteins predicted from genomic 
ortholog comparisons among 17 environmental and pathogenic bacteria. These expressed 
proteins showed exclusive relationships among the content of phenotypically related bacteria, 
which is indicative of the specific lifestyles associated with these organisms. It was 
demonstrated that proteomic studies would be able to establish expressed lifestyle differences 
among conserved genes [27]. 
 
Bioinformatic analysis of the intergenic regions of several S. aureus strains showed the 
expression of 11 novel, stable and Hfq-independent, noncoding RNAs (RsaA-K) in the late-
exponential phase of growth. The transcription was regulated by the alternative B factor 
(RsaA, D and F) in the majority of cases and the expression of RsaE is agrA-dependent. This 
transcriptomic and proteomic analysis indicated that RsaE regulates the synthesis of proteins 
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involved in various metabolic pathways. Phylogenetic analysis conducted in this study 
showed that most of the novel ncRNAs carry the conserved C–rich motif which was linked to 
members of a class of ncRNAs that target mRNAs by a shared mechanism [21].  The ability 
of bioinformatics to characterize genomic sequences from pathogenic bacteria for the 
prediction of genes that may encode vaccine candidates, e.g. surface localized proteins, has 
been evaluated [28, 29]. A combination of genomic, proteomic and bioinformatics led to the 
identification of a putative vaccine candidate, the outer membrane lipoprotein P6, for 
Haemophilus influenzae [30, 31]. The application of proteomic and bioinformatic techniques 
for the identification of vaccine candidates for another pathogenic bacterium, Helicobacter 
pylori, has also demonstrated that utilization of bioinformatics to study genomes and 
proteomics is a useful approach for vaccine discovery [32]. Similar approaches would be 
useful to investigate S. aureus proteomics aiming vaccine candidate protein or group of 
proteins. 
 
4. MRSA PROTEOMICS 
Proteomics is an ideal tool to analyse differences in gene expression between bacterial 
strains with different phenotypes. Generally S. aureus strains are grouped on the basis of their 
sensitivity to methicillin; methicillin-susceptible S. aureus (MSSA) and methicillin-resistant 
S. aureus (MRSA). Currently, the focus is on strains causing disease in the community, 
MRSA in particular (Table 1). It is not always true that MRSA strains are more virulent than 
methicillin-susceptible S. aureus strains. However, some MRSA strains contain factors or 
genetic backgrounds that may enhance their virulence or ability to cause particular diseases 
[40]. The latest technological advances in proteomic tools would be helpful for researchers to 
elucidate the complex molecular mechanisms involved in virulence and the resistance of 
MRSA [17]. Cordwell et al. [33] used 2DE analysis combined with Mass-Spectrometry to 
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map the proteins of methicillin-resistant (COL) and methicillin-susceptible (8325) strains of 
S. aureus.. A total of 377 proteins were identified including 266 distinct ORFs corresponding 
to proteins and 14 potential virulence factor proteins. Strain COL showed deferential 
expression of 12 protein spots, which included alkaline-shock protein 23 (Asp23) and cold-
shock proteins CspABC. These proteins either were not present or were in significantly lower 
intensity in the methicillin-susceptible strain 8325.  These comparative maps were used to 
characterize the S. aureus response to treatment with Triton X-100 (TX-100).  It was reported 
that 44 protein spots showed altered levels of abundance, and 11 of these spots were found 
only in COL in the presence of the detergent (TX-100). Significantly altered levels of the 
gene products regulated by B (the alternative sigma factor), including Asp23 and three 
proteins of unknown function, and SarA (a regulator of virulence genes) were observed in this 
study. The production of the essential methicillin-resistance factor FemA was not affected by 
growth of both strains in the presence of TX-100. This study suggested that proteins such as 
B, sarA regulons along with other factors could be involved in methicillin resistance in S. 
aureus.  
A comparative proteomic analyses of the expression of SAV2095 mRNA levels between 
25 MRSA and vancomycin-intermediate Staphylococcus aureus (VISA)/heterogeneous VISA 
clinical isolates revealed high induction of  SAV2095 mRNA in all VISA isolates relative to 
all MRSA strains (p < 0.001), and in several potential heterogeneous VISA strains.  Increases 
in levels of SAV2095 expression in four unrelated clinical MRSA isolates displayed 
increasing levels of resistance to vancomycin.  The results of this study suggested that 
SAV2095 expression levels could serve as a molecular diagnostic marker for the rapid 
detection of VISA [34]. This demonstrates the applications of proteomics in differentiating 
pathogens with varying levels of virulence abilities. 
Immunological assays in conjunction with proteomics analysis were used in a study by 
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Glowalla et al. [35], which attempted to identify novel vaccine candidates. This approach 
used intravenous immunoglobulin (IVIG) preparation as a source of antibodies directed 
against anchorless S. aureus surface proteins and a subtractive proteome analysis (SUPRA) 
technique was employed to identify these proteins. Three candidate proteins (out of 40 
proteins preselected on these basis of MALDI-TOF analysis), enolase (Eno), oxoacyl 
reductase (Oxo), and hypothetical protein hp2160, were expressed as glutathione S-
transferase fusion proteins, purified, and used for enrichment of corresponding 
immunoglobulin Gs from IVIG by affinity chromatography. It was suggested that anchorless 
cell wall proteins along with identification of more target proteins in future evaluation by the 
SUPRA technique would be valuable in the formulation of a multivalent vaccine.  
 
5. APPLICATION OF PROTEOMICS IN S. AUREUS VIRULENCE MECHANISM 
INVESTIGATIONS AND VACCINE DISCOVERY 
To date the role of different virulence factors of this versatile pathogen in the 
development of staphylococcal infections remains poorly understood. Moreover, genomic 
approaches to vaccine development, termed “reverse vaccinology”, has not resulted in the 
successful development of an anti-staphylococcal vaccine [41, 42]. This approach entails the 
mining of genomic data in silico to help identify proteins encoded by a microorganism.  
However, proteomic technologies can serve as an important complement to the reverse 
vaccinology approach to antigen discovery. Proteomic techniques have the ability to identify 
protein expression by the pathogen to infect a host as well as the surface associated protein of 
the pathogen. These two groups of proteins could play a vital role in vaccine antigen selection 
to boost host immune response for a better protection against the pathogen [43].  A schematic 
illustration of such a proteomic approach to develop a vaccine is shown in Figure 1.  
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Protein expression in bacteria has been extensively documented using different proteomic 
techniques. This has resulted in datasets reporting up to 40 to 60% of the theoretical proteome 
of S. aureus [13]. Inherently, there are some limitations with respect to the proteome 
coverage of 2DE-based maps. An analysis of the identified proteins using Transmembrane 
Hidden Markov Model (TMHMM) 2.0 [44] shows that proteins with helical trans-membrane 
domains are highly under-represented. While around 700 proteins or 25% of the theoretical 
proteome of S. aureus are predicted to contain at least one helical trans-membrane domain, of 
which only 16 proteins have been identified [45].  This is in accordance with many previous 
observations that 2DE is not an adequate approach for the profiling of membrane proteins. 
Conventional proteomic methodologies use 2DE gels to separate bacterial cell components 
followed by the identification of immunoreactive spots by mass spectrometry. These methods 
are only able to sample proteins which are produced by the bacterium in broth culture in the 
laboratory. Different proteins that are only expressed in an animal or human host will not be 
available for analysis. Although bioinformatic tools can predict the cellular location of 
bacterial proteins using homology searches, they are not capable of providing a perfect 
indication of protein subcellular localization. It is of utmost importance to characterize 
membrane, surface-associated and secretory proteins of S. aureus because these sub-
proteomes substantially determine its virulence, and can be used as diagnostic targets or serve 
as vaccine candidates.  
Use of proteomic approaches to study S. aureus is limited to metabolic studies and 
identification of drug targets. A comprehensive proteome map is an essential tool for a better 
understanding of the cell physiology of this human pathogen [2].  Thus progress in bacterial 
proteomics will be highly beneficial for medical research in particular to evaluate virulence in 
resistant strains in a single experiment [46]. There is still a long way to go for fine-tuning 
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proteomic applications in this area before we start to understand infection, pathogenesis and 
adaptation of S. aureus [18].   
 
6. CONCLUSION 
A pan-proteome concept can be instrumental in providing a novel selection criterion for 
the identification of potential diagnostic, therapeutic and vaccine targets. An emerging field 
of study is population proteomics. This discipline tries to address the spatial and/or temporal 
structure of populations (meta-populations) at the protein level. It is anticipated that such 
studies will overcome the apparent separation between population genomics and proteomics. 
The knowledge gained from a “pan-proteomic” approach will enable the discovery of targets 
that are essential to the bacterial organism to cause an in-vivo infection or to express 
virulence factors. A single proteome sequence is not entirely representative of a given 
bacterial species. As a consequence, an effective vaccine or diagnostic is only possible by 
including a combination of antigens based on the information retrieved from the pathogenic 
population structure. At the level of the expressed proteins, this diversity is even more 
spectacular. Differences in protein expression demonstrate the importance of combining 
information at different levels before determining the most relevant targets for inhibitors or 
vaccines.  
We are getting closer to a time when vaccines will not be based on a single protein 
from a single organism, but rather from a collection of conserved proteins that together 
protect against a group of organisms. Therefore further advances are needed in the current 
knowledge of the disease-causing ability of the major hospital- and community-associated 
MRSA clones found around the world.  
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Fig. (1). A Schematic Overview of Proteomics Approaches Commonly Used in Vaccine 
Discovery Investigations.  
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Table 1. Proteins Identified in Methicillin-resistant Staphylococcus aureus Strains 
Linked to Their Virulence 
 
 
Proteins/regulators identified MRSA 
strains/isolates 
Functionality/predicted 
role 
References 
B, sarA regulons S. aureus COL Involved in methicillin 
resistance 
[33] 
SAV2095 mRNA 25 MRSA clinical 
isolates 
Resistance to antibiotic 
vancomycin 
[34] 
enolase (Eno), oxoacyl reductase (Oxo), 
and hypothetical protein hp2160 
S. aureus USA300 Anchorless cell wall 
proteins 
[35] 
cytotoxins, enterotoxins, proteases, 
lipolytic enzymes, peptidoglycan 
hydrolases 
Methicillin resistance 
S. aureus COL 
Virulence factors [36] 
63 Sec-dependent extracellular proteins 25 S. aureus isolates 
from human 
infections. 
S. aureus (RN6390, 
COL and Newman) 
used as reference 
strains. 
S. aureus-associated 
virulence 
[37] 
Surface exposed proteins (the membrane 
protein FtsL, the elastin-binding protein 
EbpS, the amidase LytH and the glycerol 
phosphate lipoteichoic acid synthase 
LtaS)  
S. aureus (Newman, 
COL, RN6390, 
RN4220, NCTC8325 
and USA300) 
The targets for novel 
drugs, therapeutic 
antibodies or vaccines. 
[38] 
VraR S. aureus RN1HG Vancomycin resistance-
associated sensor/regulator 
[39] 
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